Hughes syndrome (antiphospholipid syndrome) and myocardial infarction

2010 ◽  
Vol 64 (9) ◽  
pp. 1183-1184 ◽  
Author(s):  
Graham Hughes
Angiology ◽  
2001 ◽  
Vol 52 (11) ◽  
pp. 785-788 ◽  
Author(s):  
Bruno Laganà ◽  
Luigi Baratta ◽  
Luigi Tubani ◽  
Vincenzina Golluscio ◽  
Massimo Delfino ◽  
...  

2021 ◽  
Author(s):  
R Plöger ◽  
P Kosian ◽  
D Momcilovic ◽  
J Luetkens ◽  
U Gembruch ◽  
...  

2015 ◽  
Vol 3 (4) ◽  
pp. 705-709 ◽  
Author(s):  
Marija Vavlukis ◽  
Irina Kotlar ◽  
Emilija Chaparoska ◽  
Bekim Pocesta ◽  
Hristo Pejkov ◽  
...  

AIM: We are presenting an uncommon case of pulmonary embolism, followed with an acute myocardial infarction, in a patient with progressive systemic sclerosis.CASE PRESENTATION: A female 40 years of age was admitted with signs of pulmonary embolism, confirmed with CT scan, which also reviled a thrombus in the right ventricle. The patient had medical history of systemic sclerosis since the age of 16 years. She suffered an ischemic stroke 6 years ago, but she was not taking any anticoagulant or antithrombotic medications ever since. She received a treatment with thrombolytic therapy, and subsequent UFH, but, on the second day after receiving fibrinolysis, she felt chest pain accompanied with ECG changes consistent for ST-segment elevation myocardial infarction (STEMI). Urgent coronary angiography was undertaken, which reviled cloths causing total occlusion in 4 blood vessels, followed with thromboaspiration, but without successful reperfusion. Several hours later the patient developed rapid deterioration with letal ending. During the very short hospital course, blood sampling reviled presence of antiphospholipid antibodies.CONCLUSION: The acquired antiphospholipid syndrome is common condition in patients with systemic autoimmune diseases, but relatively rare in patients with systemic sclerosis. Never the less, we have to be aware of it when treating the patients with systemic sclerosis.


2007 ◽  
Vol 83 (3) ◽  
pp. 1170-1171 ◽  
Author(s):  
Ibrahim S. Abu Romeh ◽  
Adnan K. Chhatriwalla ◽  
Fernando A. Atik ◽  
Deepak L. Bhatt ◽  
Jose L. Navia

Author(s):  
Karolina Semczuk-Kaczmarek ◽  
Anna E. Platek ◽  
Anna Ryś-Czaporowska ◽  
Filip M. Szymanski ◽  
Krzysztof J. Filipiak

Lupus ◽  
2020 ◽  
Vol 29 (12) ◽  
pp. 1493-1502
Author(s):  
Wared Nour-Eldine ◽  
Hussein A Noureldine ◽  
Batoul A Haydar ◽  
Mariam Nour Eldine ◽  
Mohammad Hassan A Noureldine ◽  
...  

Prior to 1983, several landmark reports prepared the stage for a detailed description of the Antiphospholipid (Hughes) syndrome (APS). Formerly depicted as lupus-like, APS exhibits a wide spectrum of symptoms that overlap with Sjogren’s, Hashimoto, and other autoimmune diseases. In this review, we take a glimpse into the history of description of APS, discussing the events that led to its recognition as one of the most common autoimmune diseases and the enormous impact of that recognition in the rheumatology field.


2019 ◽  
Vol 7 ◽  
pp. 232470961984224
Author(s):  
Amar Shere ◽  
Pradyumna Agasthi ◽  
Farouk Mookadam ◽  
Sudheer Konduru ◽  
Reza Arsanjani

Antiphospholipid syndrome (APS) is an autoimmune disorder that has a strong propensity for a hypercoagulable state and is known to be associated with venous and arterial thromboembolism. We describe an uncommon case of APS in the setting of non-Hodgkin’s lymphoma, with thromboembolism, and a rare complication after an uncommon etiology of myocardial infarction. This case highlights the importance of early and appropriate type of anticoagulation to reduce the morbidity and mortality in patients with APS.


Sign in / Sign up

Export Citation Format

Share Document